Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

NUCALA

MEPOLIZUMAB

Standard Dose
100MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview NUCALA is listed in Drugs@FDA under application 761122 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient MEPOLIZUMAB Form and strength INJECTABLE;SUBCUTANEOUS - 100MG/ML Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2025-08-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview NUCALA is listed in Drugs@FDA under application 761122 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient MEPOLIZUMAB Form and strength INJECTABLE;SUBCUTANEOUS - 100MG/ML Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2025-08-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.